OncoMatch/Clinical Trials/NCT03590171
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Is NCT03590171 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Bortezomib for acute lymphoblastic leukemia (all).
Treatment: Bortezomib — The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the integration of new agents.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Excluded: BCR fusion with ABL1 (t(9;22))
Breakpoint cluster region-Abelson (BCR-ABL)/ t(9;22) positive ALL
Excluded: ABL1 fusion with BCR (t(9;22))
Breakpoint cluster region-Abelson (BCR-ABL)/ t(9;22) positive ALL
Disease stage
Required: Stage 1ST RELAPSE
Meeting HR criteria any BM relapse, early/very early isolated BM relapse, very early isolated/combined extramedullary relapse
Demographics
Prior therapy
Cannot have received: allogeneic stem cell transplant
Relapse post allogeneic stem-cell transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03590171 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplant disqualifies patients from enrollment.
Are patients with BCR alterations eligible?
No. BCR fusion with ABL1 (t(9;22)) is an exclusion criterion.
Are patients with ABL1 alterations eligible?
No. ABL1 fusion with BCR (t(9;22)) is an exclusion criterion.
What disease stage is eligible?
Stage 1ST RELAPSE is required.
Is there an age limit?
Yes. Patients must be 17 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages